Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.9K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

2.0K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
2.0K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

605
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
605
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

621
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
621
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

574
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
574
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

667
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
667

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retinal findings in familial hypercholesterolemia: An exploratory case-control study.

Atherosclerosis plus·2026
Same author

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.

Journal of lipid research·2026
Same author

Cardiovascular disease and compliance with lipid-lowering therapy among young individuals with familial hypercholesterolemia in Norway - A register study.

American journal of preventive cardiology·2025
Same author

Adherence to lipid lowering therapy in primary prevention: talk with the patient, again and again.

European journal of preventive cardiology·2025
Same author

A LDL-cholesterol level above 3 mmol/L should be treated: a personal case report.

European journal of preventive cardiology·2025
Same author

Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study.

Journal of diabetes research·2024

Related Experiment Video

Updated: Apr 15, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

31.0K

Evolocumab (AMG 145) for primary hypercholesterolemia.

Gisle Langslet1, Maurice Emery, Scott M Wasserman

  • 1Lipid Clinic, Oslo University Hospital, Forskningsveien 2 B, N-0424 Oslo, Norway.

Expert Review of Cardiovascular Therapy
|April 1, 2015
PubMed
Summary

Evolocumab effectively lowers LDL-C in patients with hypercholesterolemia, showing significant reductions compared to placebo and ezetimibe. This PCSK9 inhibitor also improved other lipid markers with a safety profile similar to comparators.

Keywords:
LDL cholesterolPCSK9cardiovascular diseaseevolocumabhypercholesterolemia

More Related Videos

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.6K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.8K

Related Experiment Videos

Last Updated: Apr 15, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

31.0K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.6K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.8K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Biochemistry

Background:

  • Hypercholesterolemia poses a significant risk for cardiovascular disease.
  • Elevated low-density lipoprotein cholesterol (LDL-C) is a primary target for intervention.
  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a crucial role in regulating LDL receptors.

Purpose of the Study:

  • To evaluate the efficacy and safety of evolocumab in lowering LDL-C.
  • To assess the impact of evolocumab on other lipid parameters.
  • To investigate evolocumab's effect in patients with homozygous familial hypercholesterolemia.

Main Methods:

  • Phase II and III clinical trials involving over 6000 subjects.
  • Comparison of evolocumab with placebo and ezetimibe.
  • Assessment of lipid profiles, including LDL-C, HDL-C, and ApoA1.

Main Results:

  • Evolocumab reduced LDL-C by 50-75% versus placebo and 35-45% versus ezetimibe.
  • Significant reductions in proatherogenic lipids, including Lp(a), were observed.
  • A modest increase in HDL-C and ApoA1 was noted.
  • In homozygous familial hypercholesterolemia, LDL-C was reduced by 30%.

Conclusions:

  • Evolocumab is a highly effective LDL-C lowering therapy for hypercholesterolemia.
  • The drug demonstrates a favorable safety and tolerability profile.
  • Further data from the FOURIER trial will elucidate cardiovascular outcomes and long-term safety.